SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 277 filers reported holding SAGE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 1.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $275,000 | +15.5% | 4,500 | +164.7% | 0.01% | 0.0% |
| Q3 2019 | $238,000 | -23.5% | 1,700 | 0.0% | 0.01% | -26.3% |
| Q2 2019 | $311,000 | +15.2% | 1,700 | 0.0% | 0.02% | +11.8% |
| Q1 2019 | $270,000 | +12.5% | 1,700 | 0.0% | 0.02% | +21.4% |
| Q3 2018 | $240,000 | -9.8% | 1,700 | 0.0% | 0.01% | -12.5% |
| Q2 2018 | $266,000 | -2.9% | 1,700 | 0.0% | 0.02% | -5.9% |
| Q1 2018 | $274,000 | -2.1% | 1,700 | 0.0% | 0.02% | -5.6% |
| Q4 2017 | $280,000 | – | 1,700 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |